Fig. 7

The impact of H3K4me3 modification on anti-PD-1/anti-PD-L1 immunotherapy. (A) OS and PFS (B) analysis for high and low H3K4me3 score based on 43 melanoma patients treated with Nivolumab (anti-PD-1 anti-body). (C) The proportion of patients with response to Nivolumab in high and low H3K4me3 groups. (D) H3K4me3 score in different Nivolumab response groups. (E) The correlation of H3K4me3 with response to Nivolumab. (F) OS analysis for high and low H3K4me3 score based on 336 locally advanced or metastatic urothelial cancer patients treated with Atezolizumab (anti-PD-L1 anti-body). (G) The proportion of patients with response to Atezolizumab in high and low H3K4me3 groups. (H) The proportion of patients with distinct tumor-infiltrating immune cells (IC) in high and low H3K4me3 groups. (I) The proportion of patients with distinct tumor immune phenotypes in high and low H3K4me3 groups. (J) H3K4me3 score in different tumor immune phenotypes. (K) Correlation analysis between H3K4me3 and PD-1/PD-L1